Hep E vax provides 4 years of protection; Zimbabwe to launch HIV jab trial;

> Novavax ($NVAX) has appointed Brian Rosen as its VP of government affairs. Release

> Targovax is expanding expand an ongoing Phase I/II study of its cancer vaccine candidate. Release

> Scientists in Zimbabwe are preparing to launch the country's first-ever HIV vaccine trial. More

> A vaccine against hepatitis E provided protection against the virus for more than 4 years, researchers say. Report

And Finally... H7N9 bird flu has the makings of a pandemic virus, scientists caution. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.